GlassScriptPhysician profile
Kevin Temple
NPI 1790152346
$1,990.25
in general payments reported to CMS, 2019-2025
12 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $461 · 2023: $669 · 2024: $480 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $515.17 | 2022-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $500.83 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $298.15 | 2021-2024 | |
| Abbott Laboratories | $238.36 | 2021-2025 | Gallant, Aveir, Mitraclip |
| Merck Sharp & Dohme LLC | $139.82 | 2022-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $120.87 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $76.65 | 2024-2025 | Uptravi, Opsumit |
| Medtronic, INC. | $38.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.50 | 2023 | Jardiance |
| Boston Scientific Corporation | $18.11 | 2025 | Cds - Mct/Cem Monitoring |
| Bayer Healthcare Pharmaceuticals INC. | $16.85 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Temple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.